

# ANG-3777 Treatment Attenuates Ischemia-Reperfusion-Induced Renal Injury in Rat and Dog Models

Narayan P<sup>1</sup>, Mangino M<sup>2</sup>, and Goldberg ID<sup>1</sup>

<sup>1</sup> Angion Biomedica Corp., Uniondale, NY-11553, <sup>2</sup> Virginia Commonwealth University, Richmond, VA

## Background

HGF is an endogenous protein that is released in response to organ injury. It is the natural ligand for the c-Met receptor, which is also upregulated after injury. HGF has significant cytoprotective and anti-apoptotic effects in renal epithelial cells<sup>1,2</sup>. In preclinical models of acute kidney injury (AKI) secondary to ischemia, treatment with HGF decreased renal epithelial apoptosis and tubular necrosis, and augmented renal regeneration, improving renal function<sup>3,4</sup>. ANG-3777 is a small molecule mimetic of hepatocyte growth factor (HGF). The objective of these studies were to determine the effect of ANG-3777 treatment in ischemia-reperfusion-induced renal dysfunction [measured by blood urea nitrogen (BUN) and serum creatinine (SCr) levels], urine output, and overall mortality in rats and dogs subjected to normothermic renal ischemia and reperfusion (nRIR).

## Methods

Studies were conducted following an approved Institutional Animal Care and Use Committee (IACUC) protocol.

**Animals.** Study 1 and 2: Adult male and female Sprague-Dawley (SD) rats; Study 3: Adult Male Beagle Dogs.

**Study 1:** 32 male and 20 female SD rats were subjected to 60-min renal ischemia and 24-hr reperfusion. ANG-3777 (2 mg/kg, intravenous [IV]; N=26) or vehicle (N=26) was given pre-ischemia and 18 hours post-reperfusion. At the onset of reperfusion, the contralateral (right) kidney was excised. BUN and SCr levels, key markers of renal function, were assessed at 24 hrs pre-sacrifice.


**Study 2:** 136 SD rats were subjected to 60-min renal ischemia and 96-hr reperfusion. Animals were dosed with ANG-3777 IV (0.2, N=48; or 2 mg/kg, N=15) or vehicle (N=70) at 24-hr post-onset of reperfusion, then once daily for the next four days. Blood and urine were collected daily (24, 48, 72, and 96 hours); mortality was recorded. Normal rats (n=3) not subjected to ischemia and reperfusion, and not treated with ANG-3777 nor vehicle, were included as additional controls.

**Study 3:** 13 Beagle dogs were subjected to 120-min left kidney renal ischemia and 7 days of reperfusion. At the onset of reperfusion, the contralateral (right) kidney was excised. Dogs were randomized to one of the following groups: 1) vehicle (IV, QD, n=4), 2), ANG-3777 (10 mg/kg, IV, QD, n=4), both started at the onset of reperfusion (Day 1), or 3) ANG-3777 delayed treatment (10 mg/kg, IV, QD, n=5) started 1 day post ischemia-reperfusion (Day 2). Dogs were dosed QD until and including Day 4. Blood was collected every 24 hours from an indwelling catheter for a total of 8 days that included a day prior to ischemia-reperfusion (Day 0) and SCr and BUN was measured.

## Results


**Study 1:** ANG-3777 treatment immediately prior to ischemic injury and 18 hours post-reperfusion significantly reduced BUN levels in male rats (Figure 1) and SCr levels in both male and female rats (Figure 2) subjected to nRIR

**Figure 1: BUN Levels after 24 hours of Reperfusion in Rats Treated with ANG-3777**




The data is presented as mean ± SEM (male, n=16 and female, n=10)

**Figure 2: SCr Levels after 24 hours of Reperfusion in Rats Treated with ANG-3777**




**Study 2:** QD treatment with ANG-3777 starting 24-hours post-ischemic injury for 4 days significantly reduced BUN (Figure 3) and SCr (Figure 4) levels, increased urine output (Figure 5), and improved survival (Figure 6) in male rats subjected to nRIR

**Figure 3: BUN Levels in Rats Treated QD with ANG-3777 Initiated 24-Hours Post-reperfusion**




The data are presented as mean ± SEM. Normal rats are untreated rats that were not subjected to renal ischemia-reperfusion

**Figure 4: SCr Levels in Rats Treated QD with ANG-3777 Initiated 24-Hours Post-reperfusion**




**Figure 5: Urine Output in Rats Treated QD with ANG-3777 Initiated 24-Hours Post-reperfusion**



The data are presented as mean ± SEM. Normal rats are untreated rats that were not subjected to renal ischemia-reperfusion


**Figure 6: Survival of Rats Treated QD with ANG-3777 Initiated 24-Hours Post-reperfusion**



## Results (2)


**Study 3:** Initiating QD treatment of ANG-3777 at the onset of reperfusion or 1-day post-reperfusion significantly improved BUN and SCr levels in dogs subjected to nRIR

**Figure 7: BUN Levels in Dogs Treated QD with ANG-3777 Initiated at Onset of Reperfusion or 1-day Post-Reperfusion (delayed)**



The data is presented as mean ± SEM

**Figure 8: SCr Levels in Dogs Treated QD with ANG-3777 Initiated at Onset of Reperfusion or 1-day Post-Reperfusion (delayed)**



## Conclusion

In nRIR animal models, immediate or delayed treatment with ANG-3777 resulted in a statistically significant improvement in:

1. Markers of renal function (SCr and BUN levels) in SD rats and Beagle Dogs
2. Urine output and survival in SD rats

These results provide evidence that ANG-3777 can improve kidney function after ischemia reperfusion injury. Research is currently ongoing to evaluate if these effects translate into significant treatment effects in humans experiencing AKI.

## References

1. Liu Y, Tobert E, Lin L, Thursby M, Sun A, Nakamura T, and Dworkin L. Upregulation of hepatocyte growth factor receptor: An amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure. *Kidney International*. 1999, 55, p442-453.
2. Zhou D, Tan R, Lin L, Zhou L, and Liu Y. Activation of hepatocyte growth factor receptor, c-met, in renal tubules is required for renoprotection after acute kidney injury. *Kidney International*. 2013, 84(3), 509-520.
3. de Souza Duraõ M Jr, Razavickas CV, Goncalves EA, Okano IR, Camargo Sm, Monte JC, dos Santos OF, The role of growth factors on renal tubular cells submitted to hypoxia and deprived glucose. *Ren Fail*. 2003, 25, 341-353.
4. Miller Sb, Martin Dr, Kissane J, Hammerman MR, Hepatocyte growth factor accelerates recovery from acute ischemic renal injury in rats. *Am J Physiol*. 1994, 266, F129-34.